EGFR and non-small cell lung carcinoma: In a randomized clinical trial, newly diagnosed advanced EGFR-mutant NSCLC patients were treated with a first-generation TKI with or without primary and metastases radiotherapy, revealing that up-front local radiotherapy significantly prolonged PFS (20.2 months versus 12.5 months) and OS (25.5 months versus 17.4 months) [25].